TICKERNOMICS Sign up
Last Update: 2024-12-27 15:28:41
AN2 Therapeutics Inc. ( ANTX ) https://www.an2therapeutics.com
1.38USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-93.40%
ANTX
SPY
32.66%
ANTX
0.00%
SPY
108.59%
ANTX
0.00%
SPY
302.52%
ANTX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
40.58
-52.84
0.10
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.67
253.65
0.46
-10.72
0.00
2.24
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-19850.00
50.00
-7356.87
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
23.65
-56.53
0.00
Other Earnings and Cash Flow Stats:
AN2 Therapeutics Inc. ( ANTX ) Net Income TTM ($MM) is -60.70
AN2 Therapeutics Inc. ( ANTX ) Operating Income TTM ($MM) is -67.00
AN2 Therapeutics Inc. ( ANTX ) Owners' Earnings Annual ($MM) is 0.00
AN2 Therapeutics Inc. ( ANTX ) Current Price to Owners' Earnings ratio is 0.00
AN2 Therapeutics Inc. ( ANTX ) EBITDA TTM ($MM) is -30.57
AN2 Therapeutics Inc. ( ANTX ) EBITDA Margin is -7356.87%
Capital Allocation:
AN2 Therapeutics Inc. ( ANTX ) has paid 0.00 dividends per share and bought back -4.195748 million shares in the past 12 months
AN2 Therapeutics Inc. ( ANTX ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
AN2 Therapeutics Inc. ( ANTX ) Interest-bearing Debt ($MM) as of last quarter is 0
AN2 Therapeutics Inc. ( ANTX ) Annual Working Capital Investments ($MM) are 19
AN2 Therapeutics Inc. ( ANTX ) Book Value ($MM) as of last quarter is 87
AN2 Therapeutics Inc. ( ANTX ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
AN2 Therapeutics Inc. ( ANTX ) has 33 million in cash on hand as of last quarter
AN2 Therapeutics Inc. ( ANTX ) has 10 million of liabilities due within 12 months, and long term debt 0 as of last quarter
AN2 Therapeutics Inc. ( ANTX ) has 29 common shares outstanding as of last quarter
AN2 Therapeutics Inc. ( ANTX ) has 0 million USD of preferred stock value
Academic Scores:
AN2 Therapeutics Inc. ( ANTX ) Altman Z-Score is -1.43 as of last quarter
AN2 Therapeutics Inc. ( ANTX ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
AN2 Therapeutics Inc. ( ANTX ) largest shareholder is owning shares at 0.00 ($MM) value
Readnour Robin Shane(an insider) Bought 5000 shares of AN2 Therapeutics Inc. ( ANTX ) for the amount of $7467.50 on 2024-12-10
21.64% of AN2 Therapeutics Inc. ( ANTX ) is held by insiders, and 52.31% is held by institutions
AN2 Therapeutics Inc. ( ANTX ) went public on 2022-03-25
Other AN2 Therapeutics Inc. ( ANTX ) financial metrics:
FCF:-62.05
Unlevered Free Cash Flow:0.00
EPS:-1.71
Operating Margin:-19850.00
Gross Profit Margin:50.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-58.16
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About AN2 Therapeutics Inc. ( ANTX ) :
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.